MedPath

RELENZA

RELENZA

Approved
DIN Number

02240863

Drug Class

Human

Market Date

Dec 7, 1999

Company
HC

GlaxoSmithKline Inc

Product Information

Detailed information about this Health Canada approved drug product, including dosage form, route of administration, and regulatory classification.

Product Details

Health Canada regulatory and product classification information

Regulatory Identifiers
DIN Number02240863
AIG Number0138401001
Classification & Schedule
C
Drug Class
Human
S
Schedule
Prescription
A
ATC Code
J05AH01 ZANAMIVIR
Product Specifications
Dosage FormPowder
Route of AdministrationOral ,  Inhalation
AHFS Classification08:18.28
Health Canada Classification

ACTIVE INGREDIENTS (1)

ZANAMIVIRActive
Strength: 5 MG / ACT
Monograph: ZANAMIVIR

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.